ENGN Stock Forecast & Price Target

enGene Therapeutics is facing risks in achieving their price target due to a decline in efficacy metrics in their latest interim analysis for their drug detalimogene. This lack of efficacy may also lead to increased uncertainty and regulatory hurdles for the drug, while facing competition and a potential need for additional funding. While there is potential for enGene to address an unmet need in the treatment of NMIBC, the recent data raise questions about their ability to compete in the market and achieve a significant market share.

enGene Therapeutics is currently in the early stages of clinical development and has not yet received any regulatory approvals for its products. It also faces competition from other companies and technologies in the field of gene therapy. Additionally, the company's financials show a significant increase in operating expenses and net losses, which could indicate potential financial instability. Furthermore, the potential decrease in durability seen in the company's latest data may negatively impact its approval and adoption in the market. These factors contribute to a negative outlook on enGene Therapeutics's stock.